Last update 05 Nov 2024

Trabedersen

Last update 05 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

ASO

Synonyms

TGF-beta antisense, Trabedersen (INN/BAN), A-12009 FREE ACID

+ [6]

Target

TGF-β2

Mechanism

TGF-β2 inhibitors(Transforming growth factor beta 2 inhibitors)

Therapeutic Areas

NeoplasmsNervous System DiseasesDigestive System Disorders+ [4]

Active Indication

MelanomaPancreatic CancerPancreatic Ductal Adenocarcinoma+ [5]

Inactive Indication

Colorectal CancerCOVID-19Hemophilia B+ [3]

Originator Organization

Isarna Therapeutics GmbH

Active Organization

Oncotelic Therapeutics, Inc.

Isarna Therapeutics GmbH

Oncotelic, Inc.

Inactive Organization

Autotelic, Inc.

Development Center for Biotechnology

Drug Highest PhasePhase 3

First Approval Date-

RegulationOrphan Drug (US), Rare Pediatric Disease (US)

Gene Sequence

Sequence Code 29532696

Source: *****

Clinical Trials associated with Trabedersen

NCT05425576 / Not yet recruitingPhase 2

Phase 2 Trial of TGF-β Inhibition (OT-101) With Anti-PD-1 (Pembrolizumab) in Patients With Malignant Pleural Mesothelioma (MPM) Failing to Achieve or Maintain Response to Checkpoint Inhibition

This is a study of OT-101, a TGF-b2 inhibitor in combination of pembrolizumab in patients with malignant pleural mesothelioma. Both efficacy assessment, and safety and tolerability of various dose of OT-101 in combination of pembrolizumab are evaluated.

Start Date01 Jun 2025

Sponsor / Collaborator

Oncotelic Therapeutics, Inc.

NCT06579196 / Not yet recruitingPhase 1/2IIT

Evaluation of Trabedersen (OT-101) With Pembrolizumab in Patients With Newly Diagnosed Advanced Non-Small Cell Lung Cancer and Positive PD-L1

The goal of this clinical trial is to: 1) evaluate the safety and recommended dose of the drug OT-101/Trabedersen when combined with Pembrolizumab and 2) determine the efficacy of the combination therapy in adults with certain types of Non-Small Cell Lung Cancer. The main question(s) it aims to answer are:
* What medical problems to participants have when taking OT101 together with Pembrolizumab?
* What is the correct dose of OT-101 to use when evaluating the safety and efficacy of the combination therapy?
* Does the combination therapy delay progression or relapse of the participant's Non-Small Cell Lung Cancer?
Participants will:
* Receive intravenous OT-101/Trabedersen for 4 days once every 2 weeks. Clinic visits are required to receive and disconnect the infusion.
* Receive intravenous Pembrolizumab once every 6 weeks.

Start Date01 Jan 2025

Sponsor / Collaborator

University of Nebraska

NCT06079346 / RecruitingPhase 2/3

A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer.

Start Date01 May 2024

Sponsor / Collaborator

Oncotelic Therapeutics, Inc.

100 Clinical Results associated with Trabedersen

100 Translational Medicine associated with Trabedersen

100 Patents (Medical) associated with Trabedersen

Literatures (Medical) associated with Trabedersen

01 Jan 2023·Methods in molecular biology (Clifton, N.J.)

Visualization of Differentiated Cells in 3D and 2D Intestinal Organoid Cultures.

Article

Author: Sato, Toshiro ; Sugimoto, Shinya ; Hanyu, Hikaru

The intestinal epithelium maintains self-renewal and differentiation capacities via coordination of key signaling pathways, including the Wnt, bone morphogenetic protein (BMP), epidermal growth factor (EGF), and Notch signaling pathways. Based on this understanding, a combination of stem cell niche factors, EGF, Noggin, and the Wnt agonist R-spondin was shown to enable the growth of mouse intestinal stem cells and the formation of organoids with indefinite self-renewal and full differentiation capacity. Two small-molecule inhibitors, including a p38 inhibitor and a TGF-beta inhibitor, were added to propagate cultured human intestinal epithelium but at the cost of differentiation capacity. There have been improvements in culture conditions to overcome these issues. Substitution of the EGF and a p38 inhibitor with insulin-like growth factor-1 (IGF-1) and fibroblast growth factor-2 (FGF-2) enabled multilineage differentiation. Monolayer culture with mechanical flow to the apical epithelium promoted the formation of villus-like structures with mature enterocyte gene expression. Here, we summarize our recent technological improvements in human intestinal organoid culture that will deepen the understanding of intestinal homeostasis and diseases.

01 May 2022·Matrix biology : journal of the International Society for Matrix BiologyQ1 · BIOLOGY

Corneal fibroblast collagen type IV negative feedback modulation of TGF beta: A fibrosis modulating system likely active in other organs

Q1 · BIOLOGY

Review

Author: Sampaio, Lycia Pedral ; Hilgert, Guilherme S L ; Wilson, Steven E ; Shiju, Thomas M

Collagen type IV (COL IV) is a major component of basement membranes (BM) in all organs. It serves functions related to BM organization and modulates the passage of growth factors from one tissue compartment to another. COL IV binds transforming growth factor (TGF) beta-1 and TGF beta-2 and, therefore, is a major modulator of TGF beta pro-fibrotic functions. After fibrotic corneal injury, TGF beta enters into the stroma from the tears, epithelium, endothelium and/or aqueous humor and markedly upregulates COL IV production in corneal fibroblasts in the adjacent stroma far removed from BMs. It is hypothesized this non-BM stromal COL IV binds TGF beta-1 (and likely TGF beta-2) in competition with the binding of the growth factors to TGF beta cognate receptors and serves as a negative feedback regulatory pathway to mitigate the effects of TGF beta on stromal cells, including reducing the developmental transition of corneal fibroblasts and fibrocytes into myofibroblasts. Losartan, a known TGF beta signaling inhibitor, when applied topically to the cornea after fibrotic injury, alters this COL IV-TGF beta pathway by down-regulating COL IV production by corneal fibroblasts. Non-BM COL IV produced in response to injuries in other organs, including the lung, skin, liver, kidney, and gut, may participate in similar COL IV-TGF beta pathways and have an important role in controlling TGF beta pro-fibrotic effects in these organs.

17 Dec 2019·Current pharmaceutical designQ4 · MEDICINE

Therapeutic Potential of Targeting Transforming Growth Factor-beta in Colorectal Cancer: Rational and Progress

Q4 · MEDICINE

Review

Author: Hassanian, Seyed M ; Khorrami, Shadi ; Avan, Amir ; Gachpazan, Meysam ; Ferns, Gordon A ; Khazaei, Majid ; Kashani, Hoda

Background::

Colorectal cancer (CRC) is one of the most common types of cancer and is associated with an increasing rate of mortality. Transforming Growth Factor-Beta (TGF-β) is often upregulated in CRC, and appears to play an important role in regulating cell proliferation, migration, immune surveillance, apoptosis, cell differentiation, drug-resistance and many cellular processes that may be involved in CRC, and therefore underscores its potential value as a therapeutic target in the treatment of CRC. An increased expression of the TGF- β pathway has been associated with poor prognosis in several cancer types, including CRC.

Methods::

Here, we describe the critical role of the TGF-β pathway in CRC as well as the preclinical and clinical investigations on TGF-β inhibitors, with particular emphasis on recent findings with small-molecule inhibitors in CRC. Several TGF-β inhibitors (e.g., Trabedersen, Galunisertib, Gradalis, PF-03446962, NIS793) have been generated over the past decade for targeting this pathway.

Results::

There is accumulating evidence of the therapeutic potential of this and other TGF-β inhibitors for the treatment of other malignancies. These inhibitors might be used in combination with chemotherapy as well as with other biological agents, in order to overcome different resistance mechanisms. However, further studies are needed to identify determinants of the activity of TGF-β inhibitors, through the analysis of genetic and environmental alterations affecting TGF-β and parallel pro-cancer pathways.

Conclusion::

These studies will be critical to improving the efficacy and selectivity of current and future anticancer strategies targeting TGF-β.

News (Medical) associated with Trabedersen

28 Oct 2024

·www.globenewswire.com

ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that pancreatic cancer patients with high expression levels of either TGFB2, IRF9, or IFI27 showed improvement of median overall survival from 16-20 months to 72 months for patients with low levels of expression for both TGFB2 and either IRF9 or IFI27 validating that knockdown of IRF9 and IFI27 as therapeutic targets for TGFB2 therapeutics. https://www.mdpi.com/3003472 The publications of this series are available at Pubmed as follow: 1) TGFB2 mRNA Levels Prognostically Interact with Interferon-Alpha Receptor Activation of IRF9 and IFI27, and an Immune Checkpoint LGALS9 to Impact Overall Survival in Pancreatic Ductal Adenocarcinoma. Qazi S, Trieu V. Int J Mol Sci. 2024 Oct 18;25(20):11221. doi: 10.3390/ijms252011221. PMID: 39457004 2) Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas. Trieu V, Maida AE, Qazi S. Cancers (Basel). 2024 Mar 19;16(6):1202. doi: 10.3390/cancers16061202. PMID: 38539537 Free PMC article. 3) Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients. Qazi S, Talebi Z, Trieu V. Biomedicines. 2024 Jan 15;12(1):191. doi: 10.3390/biomedicines12010191. PMID: 38255296 Free PMC article. 4) High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Uckun FM, Qazi S, Trieu V. Cancers (Basel). 2023 Mar 9;15(6):1676. doi: 10.3390/cancers15061676. PMID: 36980562 Free PMC article. Additional information on our current phase 3 can be found at: https://www.youtube.com/watch?v=5KqdbySDRKE About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

AcquisitionPhase 3

23 Oct 2024

·www.globenewswire.com

ONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024

AGOURA HILLS, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Precision in Drug Discovery & Preclinical Summit. Dr. Wen-Han Chang, Nanomedicine Sr. Manager, and Dr. Tara Zand, Research Scientist, presented Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://events.precision-globe.com/single-event/precision-drug-discovery-preclinical-summit-san-diego##. Dr. Chang and Dr. Zand are experienced nanomedicine and precision drug development dedicated to finding the cure for pancreatic and brain cancers. https://www.linkedin.com/in/wen-han-chang-106002139/ https://www.linkedin.com/in/tara-zand-phd-512042b5/ https://www.linkedin.com/posts/precision-evolution-global-inc_pddpsummit-sandiego-precisionevolutionglobal-activity-7253106596543619072-IqP5/ About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

Acquisition

16 Sep 2024

·www.pharmaceutical-technology.com

Boehringer seeks approval for lung fibrosis drug following Phase III win

Boehringer’s nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B). Image credit: Tada Images / Shutterstock. Boehringer Ingelheim is seeking regulatory approval for nerandomilast after a Phase III trial in idiopathic pulmonary fibrosis (IPF) met its primary endpoint. Boehringer confirmed the Phase III FIBRONEER-IPF trial (NCT05321069) met its primary endpoint of improving the forced vital capacity, a measure of lung function after 52 weeks. The company plans to present full efficacy and safety data from the study in the first half of 2025. Boehringer was quick to tout that nerandomilast’s Phase III trial was the first IPF late-stage trial in a decade to meet its primary endpoint. This is not the first time Boehringer has found success in the space. Its tyrosine kinase inhibitor (TKI) Ofev (nintedanib) was approved by the US Food and Drug Administration (FDA) to treat IPF in 2014. It has since been approved in the US for interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD) and chronic interstitial lung disease. Ofev has also raked in record profits for Boehringer , last year the therapy generated €3.5bn ($3.89bn) in global sales. The Phase III FIBRONEER-IPF trial enrolled 1,177 patients with IPF randomised to receive either nerandomilast or placebo twice daily. The study’s secondary endpoint is time to the first occurrence of acute IPF exacerbation, first hospitalisation for respiratory cause, or death. See Also: Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity MaxCyte and Kamau Therapeutics sign platform license agreement Nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B). It received a breakthrough therapy designation from the US FDA for the treatment of IPF in 2022. Boehringer is also investigating nerandomilast in patients with progressive fibrosing interstitial lung diseases in a Phase III FIBRONEER-ILD trial (NCT05321082), which is due for completion by the end of the year. IPF has a high unmet need as there are only two US FDA-approved medications, Ofev and Roche’s Esbriet (pirfenidone). Whilst Roche’s TGF-beta synthesis inhibitor also secured FDA approval in 2014, it has seen its profits erode due to the introduction of generics . The drug earned SFr718m ($752m) in sales in 2022, which dropped to CHF202m ($239m) in sales last year, as per Roche’s financials. The majority of other therapies in development for IPF are in Phase II clinical trials. In May, Vicore Pharma’s Phase IIa trial of angiotensin II type 2 receptor (AT2R) agonist buloxibutid in IPF met both its primary and secondary endpoints. Bridge Biotherapeutics’ Phase II trial evaluating its autotoxin inhibitor , BBT-877 in IPF is expected to report topline data in the first half of 2025.

Phase 3Phase 2Drug ApprovalClinical ResultBreakthrough Therapy

100 Deals associated with Trabedersen

External Link

KEGG	Wiki	ATC	Drug Bank
D10203	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Ductal Adenocarcinoma	Phase 3	US	Oncotelic Therapeutics, Inc.	01 May 2024
Secondary malignant neoplasm of pancreas	Phase 3	US	Oncotelic Therapeutics, Inc.	01 May 2024
Melanoma	Phase 3	DE	Isarna Therapeutics GmbH	29 Aug 2016
Pancreatic Cancer	Phase 3	DE	Isarna Therapeutics GmbH	19 Aug 2016
Glioblastoma	Phase 3	US	Isarna Therapeutics GmbH	01 Dec 2008
Glioblastoma	Phase 3	AR	Isarna Therapeutics GmbH	01 Dec 2008
Glioblastoma	Phase 3	AT	Isarna Therapeutics GmbH	01 Dec 2008
Glioblastoma	Phase 3	BR	Isarna Therapeutics GmbH	01 Dec 2008
Glioblastoma	Phase 3	CA	Isarna Therapeutics GmbH	01 Dec 2008
Glioblastoma	Phase 3	FR	Isarna Therapeutics GmbH	01 Dec 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04801017 (C001, Corporate Publications) Manual	Phase 2	COVID-19	32	Standard of Care+OT-101	putpofkpch(ysfuekccog) = yztymhwbee efxoigmhei (ldyilcwhbl ) View more	Positive	23 Nov 2021
				Standard of Care+Placebo	putpofkpch(ysfuekccog) = lrlwygfubw efxoigmhei (ldyilcwhbl ) View more
NCT00844064 (ASCO2017)	Phase 2	Melanoma \| Colorectal Cancer \| Pancreatic Cancer Second line	37	OT-101	uretpdexpq(vonptcjlzv) = ckcpjvkqjg byipfmxakw (yrokfwvtzo )	Positive	30 May 2017
P-001 (AACR2016)	Not Applicable	Advanced Pancreatic Adenocarcinoma Third line	37	Trabedersen	avqktjzkbm(mxtqwokyqe) = riquqamdbg tzroziyuez (ckyptniupt ) View more	Positive	15 Jul 2016
				Chemotherapy	fkeifiupkc(caqkvwwkut) = pxlverwjsz ozzorhhvuj (jwsyvyxdvy )
NCT00844064 (OT-101, ASCO2016)	Phase 1	Melanoma \| Colorectal Cancer \| Pancreatic Cancer	37	Trabedersen (OT-101)	pczrpkfgkv(qwwvniipoz) = pmgdbkwojs odjqiqreko (geonweldnp )	Positive	20 May 2016
NCT00761280 (SAPPHIRE, CTgov)	Phase 3	Glioblastoma	27	Drug delivery system for administration of AP 12009+trabedersen (Trabedersen 10 µM)	ongyijjxfy(wmbkwqixhz) = pudxfdsjqz mdajvifrkf (rqkbgzzfvc, wwtblmuqnv - bscibkyedw) View more	-	22 Aug 2014
				temozolomide+lomustine+carmustine (Chemotherapy)	ongyijjxfy(wmbkwqixhz) = esofnokmuc mdajvifrkf (rqkbgzzfvc, swysfoiovk - jlopuwwesr) View more
ASCO2012	Phase 1/2	Melanoma \| Colorectal Cancer \| Pancreatic Cancer	61	Trabedersen	viwuryuktr(hjqvnynyyb) = pnvndtlpgh valudjtagg (vgfqufpybq ) View more	-	20 May 2012
AACR2011	Phase 1/2	Neoplasms	33	Trabedersen	uepsflwbeo(vzcazxetlt) = wztavexnpg avprpxjipv (lqeabjyusl )	-	15 Apr 2011
ASCO2010	Not Applicable	High grade glioma	134	Trabedersen	carzaisysm(znkbmeuvzd) = iqeygxwvro krjcnnlwip (huklkqmrmb, 18.1 - ND)	-	20 May 2010
				Standard chemotherapy (TMZ/PCV)	carzaisysm(znkbmeuvzd) = znbaauwgfr krjcnnlwip (huklkqmrmb, 9.0 - 13.2)
Phase IIb study (AACR2010)	Phase 2	High grade glioma	145	Trabedersen 10 µM	hxwmlgcxgl(azpxmpxbqd) = qotbvfpwye wqkmvdzvks (tmkfuxnxuz ) View more	Positive	15 Apr 2010
				Standard chemotherapy (TMZ or PCV)	hxwmlgcxgl(azpxmpxbqd) = fitwdqifuf wqkmvdzvks (tmkfuxnxuz ) View more
AP 12009-P001 (ASCO2008)	Phase 1/2	Pancreatic Carcinoma \| Melanoma \| Colorectal Cancer	17	AP 12009	emjdnvpqzm(myopnqxsyi) = enrvrrjkoe vosnufpwie (fyvqcksbvu ) View more	-	20 May 2008

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis